196 related articles for article (PubMed ID: 17958944)
41. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
[TBL] [Abstract][Full Text] [Related]
42. [Validation of the Japanese SF-36 v2 acute form in patients with chronic kidney disease].
Hasegawa T; Suzukamo Y; Akizawa T; Fukuhara S
Nihon Jinzo Gakkai Shi; 2008; 50(1):42-50. PubMed ID: 18318243
[TBL] [Abstract][Full Text] [Related]
43. Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney disease.
Foley RN
Rev Cardiovasc Med; 2005; 6 Suppl 3():S27-34. PubMed ID: 16340936
[TBL] [Abstract][Full Text] [Related]
44. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
Kimel M; Leidy NK; Mannix S; Dixon J
Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
[TBL] [Abstract][Full Text] [Related]
45. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial.
Foley RN; Curtis BM; Parfrey PS
Clin J Am Soc Nephrol; 2009 Apr; 4(4):726-33. PubMed ID: 19339412
[TBL] [Abstract][Full Text] [Related]
46. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
[TBL] [Abstract][Full Text] [Related]
47. The relationship between patient knowledge of hemoglobin levels and health-related quality of life.
Kallich J; McDermott A; Xu X; Fayers P; Cella D
Qual Life Res; 2006 Feb; 15(1):57-68. PubMed ID: 16411031
[TBL] [Abstract][Full Text] [Related]
48. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review.
Gandra SR; Finkelstein FO; Bennett AV; Lewis EF; Brazg T; Martin ML
Am J Kidney Dis; 2010 Mar; 55(3):519-34. PubMed ID: 20031287
[TBL] [Abstract][Full Text] [Related]
49. Anemia treatment with darbepoetin alpha in pregnant female with chronic renal failure: report of two cases.
Sobiło-Jarek L; Popowska-Drojecka J; Muszytowski M; Wanic-Kossowska M; Kobelski M; Czekalski S
Adv Med Sci; 2006; 51():309-11. PubMed ID: 17357331
[TBL] [Abstract][Full Text] [Related]
50. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia.
Eriksson D; Goldsmith D; Teitsson S; Jackson J; van Nooten F
BMC Nephrol; 2016 Jul; 17(1):97. PubMed ID: 27460779
[TBL] [Abstract][Full Text] [Related]
51. Attitude of physicians in Saudi Arabia towards anemia treatment strategies in patients with chronic kidney disease.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):65-72. PubMed ID: 17237894
[TBL] [Abstract][Full Text] [Related]
52. Effect of darbepoetin alfa on physical function in patients undergoing surgery for colorectal cancer. A randomized, double-blind, placebo-controlled study.
Norager CB; Jensen MB; Madsen MR; Qvist N; Laurberg S
Oncology; 2006; 71(3-4):212-20. PubMed ID: 17641543
[TBL] [Abstract][Full Text] [Related]
53. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials.
Cella D; Kallich J; McDermott A; Xu X
Ann Oncol; 2004 Jun; 15(6):979-86. PubMed ID: 15151958
[TBL] [Abstract][Full Text] [Related]
54. Psychological outcomes associated with anemia-related fatigue in cancer patients.
Kallich JD; Tchekmedyian NS; Damiano AM; Shi J; Black JT; Erder MH
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):117-24. PubMed ID: 12380961
[TBL] [Abstract][Full Text] [Related]
55. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis.
Clement FM; Klarenbach S; Tonelli M; Johnson JA; Manns BJ
Arch Intern Med; 2009 Jun; 169(12):1104-12. PubMed ID: 19546410
[TBL] [Abstract][Full Text] [Related]
56. [How to best use ESA in dialyse patients? What are the criterions of choice? What is the role of the age, the nephropathy and the dialysis modality? What are the current recommendations?].
Canaud B; Leray-Moraguès H; Chenine L; Henriet D; Formet C; Crougnaud V
Nephrol Ther; 2006 Sep; 2 Suppl 4():S249-55. PubMed ID: 17373266
[TBL] [Abstract][Full Text] [Related]
57. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
Nagano N
Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
[No Abstract] [Full Text] [Related]
58. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review.
Ross SD; Fahrbach K; Frame D; Scheye R; Connelly JE; Glaspy J
Clin Ther; 2003 Jun; 25(6):1786-805. PubMed ID: 12860499
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of an anemia algorithm in chronic hemodialysis patients.
Nhan J; Jensen L; McMahon A
CANNT J; 2007; 17(3):48-58, 62-73; quiz 59-61, 74-6. PubMed ID: 17944348
[TBL] [Abstract][Full Text] [Related]
60. Anemia management and chronic renal failure progression.
Rossert J; Froissart M; Jacquot C
Kidney Int Suppl; 2005 Dec; (99):S76-81. PubMed ID: 16336582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
